• O Glehen, V Schreiber, E Cotte, A C Sayag-Beaujard, D Osinsky, G Freyer, Y François, J Vignal, and F N Gilly.
• Department of Surgery, Centre Hospitalier Lyon-Sud, Pierre Bénite, France.
• Arch Surg Chicago. 2004 Jan 1; 139 (1): 20-6.

HypothesisThe most common cause of palliative resection and recurrence in gastric cancer is peritoneal seeding. This study evaluates the efficacy of intraperitoneal chemohyperthermia after cytoreductive surgery in patients with peritoneal carcinomatosis arising from gastric cancer.DesignProspective clinical trial.SettingSurgical department at a university academic hospital.PatientsForty-nine consecutive patients with peritoneal carcinomatosis treated between January 1, 1989, and February 29, 2000.InterventionsAll patients underwent intraperitoneal chemohyperthermia with mitomycin C (40-60 mg); 21 patients had previously undergone extensive cytoreductive surgery.Main Outcome MeasuresClinicopathologic factors that affect overall survival rates.ResultsWith median follow-up of 99 months, overall median survival was 10.3 months. Two factors were significant independent predictors of survival by multivariate analysis: preoperative ascites (P =.04) and completeness of cancer resection (CCR) by cytoreductive surgery (P<.001). Median survival was 21.3 months for patients with CCR-0 (macroscopic complete resection) or CCR-1 (diameter of residual nodules <5 mm) and 6.1 months for patients with CCR-2 (diameter of residual nodules >5 mm) (P<.001). Four patients survived longer than 5 years.ConclusionsAn aggressive management strategy combining intraperitoneal chemohyperthermia with cytoreductive surgery is effective for patients with peritoneal carcinomatosis arising from gastric cancer. In highly selected patients (good general status, resectable primary tumor, resectable peritoneal carcinomatosis), this therapy may result in long-term survival.

34 keywords...

hide…